Plant medicine usage of people living with type 2 diabetes mellitus in Belize: A qualitative exploratory study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
07
2022
accepted:
14
07
2023
medline:
7
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Type 2 Diabetes Mellitus (T2DM) is a primary cause of death in Belize, a low-income country with the highest rates in Central and South America. As many people in Belize cannot consistently access biomedical treatment, a reality that was exacerbated by the COVID-19 pandemic, plant medicine usage is estimated to have increased in recent years. This exploratory study seeks to understand which plants are being used, patterns of usage, and the state of patient-provider communication around this phenomenon. Implementing a Constructivist Grounded Theory qualitative design, the research team conducted 35 semi-structured interviews with adults living with T2DM, 25 informant discussions, and participant observation with field notes between February 2020 and September 2021. Data analysis followed systematized thematic coding procedures using Dedoose analytic software and iterative verification processes. The findings revealed that 85.7% of participants used plants in their T2DM self-management. There were three main usage patterns, namely, exclusive plant use (31.4%), complementary plant use (42.9%), and minimal plant use (11.4%), related to factors impacting pharmaceutical usage. Almost none of participants discussed their plant medicine usage with their health care providers. Plant species are outlined, as are patients' reasons for not disclosing usage to providers. There are implications for the advancement of understanding ethnobotanical medicine use for T2DM self-management and treatment in Belize and beyond.
Sections du résumé
BACKGROUND
Type 2 Diabetes Mellitus (T2DM) is a primary cause of death in Belize, a low-income country with the highest rates in Central and South America. As many people in Belize cannot consistently access biomedical treatment, a reality that was exacerbated by the COVID-19 pandemic, plant medicine usage is estimated to have increased in recent years. This exploratory study seeks to understand which plants are being used, patterns of usage, and the state of patient-provider communication around this phenomenon.
METHODS
Implementing a Constructivist Grounded Theory qualitative design, the research team conducted 35 semi-structured interviews with adults living with T2DM, 25 informant discussions, and participant observation with field notes between February 2020 and September 2021. Data analysis followed systematized thematic coding procedures using Dedoose analytic software and iterative verification processes.
RESULTS
The findings revealed that 85.7% of participants used plants in their T2DM self-management. There were three main usage patterns, namely, exclusive plant use (31.4%), complementary plant use (42.9%), and minimal plant use (11.4%), related to factors impacting pharmaceutical usage. Almost none of participants discussed their plant medicine usage with their health care providers.
CONCLUSIONS
Plant species are outlined, as are patients' reasons for not disclosing usage to providers. There are implications for the advancement of understanding ethnobotanical medicine use for T2DM self-management and treatment in Belize and beyond.
Identifiants
pubmed: 37535596
doi: 10.1371/journal.pone.0289212
pii: PONE-D-22-20515
pmc: PMC10399819
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0289212Subventions
Organisme : CIHR
ID : FRN 130797
Pays : Canada
Informations de copyright
Copyright: © 2023 Allen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Glob Public Health. 2013;8(9):1063-74
pubmed: 24028377
Diabetes Metab Syndr Obes. 2021 Oct 22;14:4335-4349
pubmed: 34712054
J Ethnobiol Ethnomed. 2006 Oct 13;2:45
pubmed: 17040567
CMAJ. 2020 Mar 2;192(9):E208-E216
pubmed: 32122977
J Ethnopharmacol. 2016 May 26;184:58-71
pubmed: 26924564
Nurs Health Care Perspect. 1998 Jul-Aug;19(4):178-85
pubmed: 10446559
Rural Remote Health. 2017 Jul-Sep;17(3):4044
pubmed: 28780876
Electron Physician. 2016 Jan 15;8(1):1832-42
pubmed: 26955456
Afr J AIDS Res. 2008 Nov;7(3):281-91
pubmed: 25875456
J Ethnobiol Ethnomed. 2007 Sep 05;3:31
pubmed: 17803820
Front Pharmacol. 2021 Nov 26;12:777561
pubmed: 34899340
J Ethnobiol Ethnomed. 2015 Sep 15;11:67
pubmed: 26369926
Arch Physiol Biochem. 2018 Dec;124(5):383-389
pubmed: 29268636
Soc Sci Med. 2015 Feb;126:9-16
pubmed: 25497726
Biomed Res Int. 2015;2015:381040
pubmed: 25629046
J Ethnobiol Ethnomed. 2014 May 06;10:38
pubmed: 24885355
Cult Med Psychiatry. 2015 Sep;39(3):449-86
pubmed: 25676172
Afr J Tradit Complement Altern Med. 2014 Jun 04;11(4):1-8
pubmed: 25392573
Int J Equity Health. 2019 Nov 14;18(1):174
pubmed: 31727076
Global Health. 2017 Sep 05;13(1):69
pubmed: 28870225
Med Anthropol. 2014;33(2):92-108
pubmed: 24512380
J Ethnopharmacol. 2018 Oct 5;224:504-511
pubmed: 29936054